Tirzepatide

Tirzepatide activates two incretin receptors: GLP-1, like semaglutide, and also GIP (glucose-dependent insulinotropic polypeptide). Both pathways improve glucose-dependent insulin secretion and influence appetite, and the working hypothesis is that engaging GIP alongside GLP-1 produces greater appetite suppression and metabolic effect than GLP-1 alone. The molecule is engineered for once-weekly dosing. Exactly how much each receptor contributes in humans is still debated — but the clinical result of the combination is well documented.

Two trials matter most here, and both are strong. SURMOUNT-1 (Jastreboff et al., 2022, NEJM) tested tirzepatide in adults with obesity but without diabetes: at the 15 mg dose, mean weight reduction was about 20.9% over 72 weeks versus placebo — pushing into territory previously associated only with bariatric surgery. SURPASS-2 (Frías et al., 2021, NEJM) is the one that earned tirzepatide its reputation: a direct head-to-head against semaglutide 1 mg in type 2 diabetes, where tirzepatide produced greater reductions in both HbA1c and body weight. Head-to-head superiority data against the previous class leader is rare and credible. This is human-RCT evidence at the highest tier the site grades — the caveats are about safety and cost, not about whether it works.

• Mean ~20.9% body-weight reduction at 15 mg in obesity without diabetes (SURMOUNT-1, 72 weeks)
• Superior HbA1c and weight reduction versus semaglutide 1 mg head-to-head (SURPASS-2)
• Large proportions of participants reaching ≥15% and ≥20% weight-loss thresholds
• Improvements in waist circumference, lipids, and blood pressure tracking the weight loss

• Boxed warning: GLP-1/GIP incretins caused thyroid C-cell tumors in rodents; contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
• GI effects (nausea, vomiting, diarrhea, constipation) are the most common adverse events, worst during dose escalation
• Reports of acute pancreatitis; discontinue if suspected
• Gallbladder disease (cholelithiasis) can occur, partly linked to rapid weight loss
• Prescription drug — appropriate use is under a licensed clinician; grey-market sourcing is unsafe and outside the legal channel
• Weight regain is common after discontinuation without sustained lifestyle change

FDA-approved. Approved by the FDA for one or more human indications.

Goals studied: Fat loss, Body composition, Visceral fat reduction

What is the difference between Mounjaro and Zepbound?

Both are tirzepatide. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. The active molecule and dosing are the same — the brand and approved indication differ.

Is tirzepatide actually better than semaglutide?

On the measured endpoints, the head-to-head SURPASS-2 trial showed greater HbA1c and weight reduction with tirzepatide than semaglutide 1 mg in type 2 diabetes, and its obesity-trial weight loss (~21%) is higher than semaglutide's (~15%). The comparison is favorable — but note SURPASS-2 used a 1 mg semaglutide dose, not the 2.4 mg weight-management dose, so cross-trial weight comparisons are not perfectly clean.

Can I get tirzepatide without a prescription?

Not legally or safely. It is a prescription drug with a boxed thyroid warning and pancreatitis risk that require medical oversight. Legitimate access is through a licensed prescriber or telehealth clinic, not a research-chemical supplier.

1. [1]
   Tirzepatide Once Weekly for the Treatment of Obesity

   Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A · The New England Journal of Medicine · 2022 · PMID 35658024 · model: human

   SURMOUNT-1 phase 3 RCT in adults with obesity without diabetes, showing a mean ~20.9% body-weight reduction at the 15 mg dose over 72 weeks versus placebo.

2. [2]
   Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

   Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K · The New England Journal of Medicine · 2021 · PMID 34170647 · model: human

   SURPASS-2 head-to-head phase 3 RCT showing tirzepatide produced greater reductions in HbA1c and body weight than semaglutide 1 mg in adults with type 2 diabetes.